



03-29-06.

TTPW  
3

PTO/SB/21 (09-04)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/549,345
	Filing Date	September 14, 2005
	First Named Inventor	Daniel Rodriguez Greve
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	05432/100M668-US1

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Copy of International Search Report Copies of 50 References (Document Nos. 1-50) Return Receipt Postcard
<b>Remarks</b>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	DARBY & DARBY P.C.		
Signature			
Printed name	Mitchell Bernstein, Ph.D.		
Date	March 28, 2006	Reg. No.	46,550

Express Mail Label No. \_\_\_\_\_ Dated: \_\_\_\_\_



Docket No.: 05432/100M668-US1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Daniel Rodriguez Greve et al.

Application No.: 10/549,345

Filed: September 14, 2005

Art Unit: Not Yet Assigned

For: SUBSTITUTED ANILINE DERIVATIVES

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

Also enclosed is an International Search Report, dated July 20, 2004, which issued during the prosecution of International Application No. PCT/DK2004/000162, which corresponds to the present application.

Documents no. 1, 3, 5, 7, 8, and 11 on the attached PTO/SB/08 are not in English. Documents 1, 7, and 11 are cited on the aforementioned International Search Report. Documents 5 and 8 include English language abstracts. A separate English language abstract is provided for document 3. Further reference to these documents is found in the specification at page 2, lines 24-25 (document 3); page 5, lines 17-24 (document 5); and page 5, lines 6-8 (document 8). Thus, the required concise explanation of the relevance of documents 1, 3, 5, 7, 8, and 11 is believed to be provided.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is “prior art” for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: March 28, 2006

Respectfully submitted,

By Michael Hunter

Mitchell Bernstein, Ph.D.

Registration No.: 46,550

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/549,345
				Filing Date	September 14, 2005
				First Named Inventor	Daniel Rodriguez Greve
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	05432/100M668-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number-Kind Code <sup>4</sup> (if known)				
	1	EP	0 386 452 B1	09-12-1990	BASF Aktiengesellschaft		
	2	EP	0 515 684 A1	12-02-1992	Chugai Seiyaku Kabushiki Kaisha		
	3	EP	0 554 543 A2	08-11-1993	ASTA Medica Aktiengesellschaft		
	4	EP	1 369 420 A1	12-10-2003	Aventis Pharma Deutschland GmbH		
	5	WO	97/15300 A2	05-01-1997	ASTA Medica Aktiengesellschaft		
	6	WO	00/39118 A1	07-06-2000	Eli Lilly and Co.		
	7	WO	01/09612 A1	02-08-2001	Arzneimittelwerk Dresden GmbH		
	8	WO	01/22953 A2	04-05-2001	ASTA Medica AG		
	9	WO	01/92526 A1	12-06-2001	Bristol-Myers Squibb Co.		
	10	WO	01/96540 A2	12-20-2001	Dupont Pharmaceuticals Co.		
	11	WO	02/18318 A1	03-07-2002	Wella Aktiengesellschaft		
	12	WO	02/49628 A2	06-27-2002	Wyeth		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
	13	American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4ed., 1994, pp. 110-13, 393-444, and 623-27.	
	14	BIALER et al., "Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI)," Epilepsy Res 2002, 51, 31-71.	
	15	BLACKBURN-MUNRO et al., "The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain," Euro J Pharmacol 2003, 460, 109-16.	
	16	CAPACIO et al., "Use of the accelerating rotarod for assessment of motor performance decrement induced by potential anticonvulsant compounds in nerve agent poisoning," Drug Chem Toxicol 1992, 15, 177-201.	
Examiner Signature			Date Considered



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/549,345	
			Filing Date	September 14, 2005	
			First Named Inventor	Daniel Rodriguez Greve	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	05432/100M668-US1

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	17	Commission on Classification and Terminology of the International League Against Epilepsy, "Proposal for revised clinical and electroencephalographic classification of epileptic seizures," <i>Epilepsia</i> 1981, 22, 489-501.	
	18	Commission on Classification and Terminology of the International League Against Epilepsy, "Proposal for revised classification of epilepsies and epileptic syndromes," <i>Epilepsia</i> 1989, 30, 389-99.	
	19	COOPER et al., "Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy," <i>Proceedings Nat Acad Sci USA</i> 2000, 97, 4914-19.	
	20	DAVOLL et al., "Folate antagonists. 2. 2,4-Diamino-6-([aralkyl and (heterocyclic)methyl]amino)quinazolines, a novel class of antimetabolites of interest in drug-resistant malaria and Chagas' disease," <i>J Med Chem</i> 1972, 15, 812-26.	
	21	EBERT et al., "Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat," <i>Epilepsia</i> 2002, 43 Suppl 5, 86-95.	
	22	GOLDSTEIN et al., "Localization of KCNQ and KCNE channel subunits in the central and peripheral nervous system of the rat," <i>Soc Neuroscience Abstracts</i> 2003, 53.8.	
	23	HAMILL et al., "Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches," <i>Phlucers Arch</i> 1981, 391, 85-100.	
	24	HARTZ et al., "The KCNQ channel opener retigabine has anxiolytic properties," <i>J Psychopharmacol</i> 2003, 17 Suppl 3, A28, B14.	
	25	JENTSCH, "Neuronal KCNQ potassium channels: physiology and role in disease," <i>Nature Rev: Neuroscience</i> 2000, 1, 21-30.	
	26	KEENEY et al., "Alterations in core body temperature, locomotor activity, and corticosterone following acute and repeated social defeat of male NMRI mice," <i>Physiol Behavior</i> 2001, 74, 177-84.	
	27	KIMBALL et al., "Biological effects of fast neutrons from an internal target cyclotron: physical methods and dominant lethals in <i>drosophila</i> ," <i>Radiation Res</i> 1957, 6, 173-87.	
	28	LITVINENKO et al., <i>Dokl Chem</i> 1981, 259, 317-320 (abstract).	
	29	MARRION, "Control of M-current," <i>Annual Rev Phys</i> 1997, 59, 483-504.	
	30	MEYER et al., "N <sup>2</sup> -(4-substituted-2,6-dichlorophenyl)-N <sup>1</sup> ,N <sup>1</sup> -dimethylformamides as antihypertensive and diuretic agents," <i>J Med Chem</i> 1984, 27, 1705-10.	
	31	NODA et al., "KCN channels in glial cells," <i>Soc Neuroscience Abstracts</i> 2003, 53.9.	
	32	NUTT et al., "Optimizing the pentetrazol infusion test for seizure threshold measurement," <i>J Pharmacy Pharmacol</i> 1986, 38, 697-98.	
	33	PORRETTA et al., "Research on anti-bacterial and anti-fungal agents II. Synthesis and anti-fungal activity of new (1H-imidazol-1-ylmethyl)-benzenamine derivatives," <i>Euro J Med Chem</i> 1998, 23, 311-17.	
	34	RACINE, "Modification of seizure activity by electrical stimulation: II. Motor seizure," <i>Electroencephalography Clin Neurophysiol</i> 1972, 32, 281-94.	
	35	ROBBINS, "KCNQ potassium channels: physiology, pathophysiology, and pharmacology," <i>Pharmacol Ther</i> 2001, 90, 1-19.	
	36	ROGAWSKI, "KCNQ2/KCNQ3 K <sup>+</sup> channels and the molecular pathogenesis of epilepsy: implications for therapy," <i>Trends in Neuroscience</i> 2000, 23, 393-98.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
				Application Number	10/549,345
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Filing Date	September 14, 2005
				First Named Inventor	Daniel Rodriguez Greve
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	05432/100M668-US1

(Use as many sheets as necessary)

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	37	ROSTOCK et al., "D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures," Epilepsy Res 1996, 23, 211-23.	
	38	SAGANICH et al., "Differential expression of genes encoding subthreshold-operating voltage-gated K <sup>+</sup> channels in brain," J Neuroscience 2001, 21, 4609-24.	
	39	SCALZO et al., "Studies on substrates with antibacterial and antifungal activity," Farmaco Edizione Scientifica 1986, 41, 292-307 (abstract).	
	40	SCHRODER et al., "KCNQ4 channel activation by BMS-204352 and retigabine," Neuropharmacol 2001, 40, 888-98.	
	41	SEYDEL et al., "Synthesis and quantitative structure-activity relationships of anticonvulsant 2,3,6-triaminopyridines," J Med Chem 1994, 37, 3016-22.	
	42	STARR et al., "Paradoxical facilitation of pilocarpine-induced seizures in the mouse by MK-801 and the nitric oxide synthesis inhibitor L-NAME," Pharmacol Biochem Behavior 1993, 45, 321-25.	
	43	TANG et al., "Development and evaluation of high throughput functional assay methods for hERG potassium channel," J Biomol Screen 2001, 6, 325-31.	
	44	TATULIAN et al., "Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine," J Neuroscience 2001, 21, 5535-45.	
	45	TOBER et al., D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures," Euro J Pharmacol 1996, 303, 163-69.	
	46	WATSON et al., "The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome," Neuropharmacol 1997, 36, 1369-75.	
	47	WICKENDEN et al., "Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels," Molec Pharmacol 2000, 58, 591-600.	
	48	WICKENDEN et al., "KCNQ channel expression in rat DRG following nerve ligation," Soc Neuroscience Abstracts 2002, 454.7.	
	49	WLAZ et al., "Frontal versus transcorneal stimulation to induce maximal electroshock seizures or kindling in mice and rats," Epilepsy Res 1998, 30, 219-29.	
	50	YIN et al., "Palladium-catalyzed intermolecular coupling of aryl halides and amides," Organic Letters 2000, 2, 1101.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Attorney Docket No.: 05432/100M668-US1

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to: 61778823827-11

EV778823627-U

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on March 28, 2006  
Date

  
Signature  
Lillian Garcia

Signature \_\_\_\_\_

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

**Note:** Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page)  
Information Disclosure Statement (2 pages)  
Form PTO/SB/08 (3 pages)  
Copy of International Search Report (5 pages)  
Copies of 50 References (Document Nos. 1-50)  
Return Receipt Postcard